×
About 377 results

ALLMedicine™ Mevalonate Kinase Deficiency Center

Research & Reviews  183 results

Gene Expression Analysis of Mevalonate Kinase Deficiency Affected Children Identifies M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908123
International Journal of Environmental Research and Publi... Pisanti S, Citro M et. al.

Feb 2nd, 2021 - Mevalonate kinase deficiency (MKD) is a rare autoinflammatory genetic disorder characterized by recurrent fever attacks and systemic inflammation with potentially severe complications. Although it is recognized that the lack of protein prenylation...

HAPLOIDENTICAL α/β T-CELL AND B-CELL STEM CELL TRANSPLANTATION IN SEVERE MEVALONATE KIN...
https://doi.org/10.1093/rheumatology/keaa912
Rheumatology (Oxford, England); Faraci M, Giardino S et. al.

Jan 7th, 2021 - Mevalonic aciduria (MA) represents the most severe of mevalonate kinase deficiency (MKD). Patients with MA have an incomplete response even to high doses of anti-cytokine drugs as anakinra or canakinumab and stem cell transplantation (SCT) represe...

Comparison of the clinical diagnostic criteria and the results of the next-generation s...
https://doi.org/10.1007/s10067-020-05492-8
Clinical Rheumatology; Sözeri B, Demir F et. al.

Nov 9th, 2020 - The clinicians initially prefer to define patients with the systemic autoinflammatory disease (SAID)'s based on recommended clinical classification criteria; then, they confirm the diagnosis with genetic testing. We aimed to compare the initial ph...

Burden of illness in hereditary periodic fevers: a multinational observational patient ...
https://www.ncbi.nlm.nih.gov/pubmed/33025894
Clinical and Experimental Rheumatology; Kuemmerle-Deschner JB, Quartier P et. al.

Oct 7th, 2020 - This study aimed to characterise the burden of illness of patients with inadequately controlled hereditary periodic fevers (HPFs), during and outside of flares. It was focused on the burden to the patients and also considered the wider impact on t...

Overview of the rarest causes of fever in newborns: handy hints for the neonatologist.
https://doi.org/10.1038/s41372-020-0744-8
Journal of Perinatology : Official Journal of the Califor... De Rose DU, Coppola M et. al.

Jul 26th, 2020 - Neonatal causes of fever are a major source of concern for clinicians. If fever is combined with organ-specific sterile inflammatory manifestations the suspicion of autoinflammatory disorders should be considered, and the list of such conditions s...

see more →

Guidelines  1 results

Consensus protocols for the diagnosis and management of the hereditary autoinflammatory...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027082
Pediatric Rheumatology Online Journal; Hansmann S, Lainka E et. al.

Feb 18th, 2020 - Rare autoinflammatory diseases (AIDs) including Cryopyrin-Associated Periodic Syndrome (CAPS), Tumor Necrosis Receptor-Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency Syndrome (MKD)/ Hyper-IgD Syndrome (HIDS) are genetically ...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  189 results

Gene Expression Analysis of Mevalonate Kinase Deficiency Affected Children Identifies M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908123
International Journal of Environmental Research and Publi... Pisanti S, Citro M et. al.

Feb 2nd, 2021 - Mevalonate kinase deficiency (MKD) is a rare autoinflammatory genetic disorder characterized by recurrent fever attacks and systemic inflammation with potentially severe complications. Although it is recognized that the lack of protein prenylation...

HAPLOIDENTICAL α/β T-CELL AND B-CELL STEM CELL TRANSPLANTATION IN SEVERE MEVALONATE KIN...
https://doi.org/10.1093/rheumatology/keaa912
Rheumatology (Oxford, England); Faraci M, Giardino S et. al.

Jan 7th, 2021 - Mevalonic aciduria (MA) represents the most severe of mevalonate kinase deficiency (MKD). Patients with MA have an incomplete response even to high doses of anti-cytokine drugs as anakinra or canakinumab and stem cell transplantation (SCT) represe...

Comparison of the clinical diagnostic criteria and the results of the next-generation s...
https://doi.org/10.1007/s10067-020-05492-8
Clinical Rheumatology; Sözeri B, Demir F et. al.

Nov 9th, 2020 - The clinicians initially prefer to define patients with the systemic autoinflammatory disease (SAID)'s based on recommended clinical classification criteria; then, they confirm the diagnosis with genetic testing. We aimed to compare the initial ph...

Burden of illness in hereditary periodic fevers: a multinational observational patient ...
https://www.ncbi.nlm.nih.gov/pubmed/33025894
Clinical and Experimental Rheumatology; Kuemmerle-Deschner JB, Quartier P et. al.

Oct 7th, 2020 - This study aimed to characterise the burden of illness of patients with inadequately controlled hereditary periodic fevers (HPFs), during and outside of flares. It was focused on the burden to the patients and also considered the wider impact on t...

Overview of the rarest causes of fever in newborns: handy hints for the neonatologist.
https://doi.org/10.1038/s41372-020-0744-8
Journal of Perinatology : Official Journal of the Califor... De Rose DU, Coppola M et. al.

Jul 26th, 2020 - Neonatal causes of fever are a major source of concern for clinicians. If fever is combined with organ-specific sterile inflammatory manifestations the suspicion of autoinflammatory disorders should be considered, and the list of such conditions s...

see more →

News  2 results

Canakinumab controls periodic fever syndromes in post-flare and maintenance dosing
https://www.mdedge.com/internalmedicine/article/118666/pain/canakinumab-controls-periodic-fever-syndromes-post-flare-and
Alice Goodman

Nov 22nd, 2016 - WASHINGTON – Prolonged dosing with canakinumab, an anti-interleukin-1beta monoclonal antibody, confirmed its efficacy in controlling flares in three rare autoinflammatory diseases grouped as periodic fever syndromes: familial Mediterranean fever,.

Canakinumab (Ilaris) Gets FDA Nod for Three Rare Periodic Fever Syndromes
https://www.medscape.com/viewarticle/869226

Sep 25th, 2016 - The US Food and Drug Administration (FDA) has approved three new indications for the interleukin-1-β inhibitor canakinumab (Ilaris, Novartis). They are tumor necrosis factor receptor–associated periodic syndrome (TRAPS), hyperimmunoglobulin D synd...

see more →